# LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

> **NCT02182622** · PHASE1 · WITHDRAWN · sponsor: **Martin Gutierrez**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Prednisone
- **DRUG:** LDE225

## Key facts

- **NCT ID:** NCT02182622
- **Lead sponsor:** Martin Gutierrez
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182622, "LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02182622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*